Page last updated: 2024-11-10

arbaprostil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Arbaprostil: A synthetic prostaglandin E analog that protects the gastric mucosa, prevents ulceration, and promotes healing of peptic ulcers. The protective effect is independent of acid inhibition. It is also a potent inhibitor of pancreatic function and can inhibit the growth of experimental tumors. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5283064
CHEMBL ID2105959
CHEBI ID184592
SCHEMBL ID563879
MeSH IDM0001657

Synonyms (47)

Synonym
arbacet
u-42842
arbastyl
arbaprostil
cu-83
55028-70-1
D02975
arbaprostil (usan/inn)
15(r)-15-methyl prostaglandin e2
arbaprostil [usan:inn]
prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-15-methyl-9-oxo-, (5z,11alpha,13e,15r)-
u 42-842
(5a,11alpha,13e,15r)-11,15-dihydroxy-15-methyl-9-oxo-5,13-prostadiensaeure
arbaprostilo [inn-spanish]
arbaprostilum [inn-latin]
u 42842
(15r)-15-methylprostaglandin e2
ccris 1921
araprostil
(e,z)-(1r,2r,3r)-7-(3-hydroxy-2-((3r)-(3-hydroxy-3-methyl-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid
15(r)-methylprostaglandin e2
15-methyl-15r-pge2
LMFA03010063
15-methyl-15r-prostaglandin e2
9-oxo-11r,15r-dihydroxy-15-methyl-5z,13e-prostadienoic acid
(z)-7-[(1r,2r,3r)-3-hydroxy-2-[(e,3r)-3-hydroxy-3-methyloct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
CHEMBL2105959
arbaprostilo
arbaprostilum
u 42,842
m6b59s6mef ,
unii-m6b59s6mef
arbaprostil [inn]
(e,z)-(1r,2r,3r)-7-[3-hydroxy-2-[(3r)-(3-hydroxy-3-methyl-1-octenyl)]-5-oxocyclopentyl]-5-heptenoic acid
arbaprostil [usan]
arbaprostil [jan]
prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-15-methyl-9-oxo-, (5z,11.alpha.,13e,15r)-
arbaprostil [mi]
arbaprostil [mart.]
SCHEMBL563879
AC-31147
HMS3648H21
SR-01000946432-1
sr-01000946432
DTXSID10866457
15(r)-15-methyl pge2
CHEBI:184592

Research Excerpts

Overview

Arbaprostil is an orally active prostaglandin E2 analogue.

ExcerptReferenceRelevance
"Arbaprostil is an orally active prostaglandin E2 analogue. "( Pharmacokinetic interactions between arbaprostil and aspirin in humans.
Cox, JW; Euler, AR; Gee, WL; Hsyu, PH; Pullen, RH,
)
1.85

Pharmacokinetics

ExcerptReferenceRelevance
" In this study, pharmacokinetic interactions between arbaprostil and aspirin were examined in humans after chronic doses of both drugs."( Pharmacokinetic interactions between arbaprostil and aspirin in humans.
Cox, JW; Euler, AR; Gee, WL; Hsyu, PH; Pullen, RH,
)
0.65

Dosage Studied

ExcerptRelevanceReference
" Severe diarrhea occurred in 1% of those patients who received the 50-micrograms dosage regimen, but in none of the other two groups."( An evaluation of arbaprostil at multiple doses for the treatment of acute duodenal ulcer: a randomized double-blind placebo-controlled international trial.
Barbara, L; Bass, D; Euler, AR; Gabryelewicz, A; Garcia, L; Gibinski, K; Gilat, T; Krawiec, J; Odes, H; Rachmilewitz, D, 1990
)
0.62
" No statistical differences were found at any dosage level in either study for average uterine resting pressures, average peak pressures, the number of contractions or Montevideo units."( Arbaprostil's [15(R)-15-methyl PGE2] effects on intrauterine pressure in the nonpregnant and pregnant human female--a report of four clinical trials.
Bogaerts, H; Burns, MD; Euler, AR; Huber, J; Kitt, M; Leodolter, S; Lookabaugh, J; Phan, TD; Wood, DR, 1989
)
1.72
" Following an initial dose-response study, a double-blind crossover trial was performed using pretreatment with placebo or with 10-micrograms doses of 15-R-15 methyl prostaglandin E2 for 24 h before treatment with aspirin."( Prevention of acute aspirin-induced gastric mucosal injury by 15-R-15 methyl prostaglandin E2: an endoscopic study.
Bergman, D; Feld, AD; Gilbert, DA; Sanford, RL; Saunders, DR; Silverstein, FE; Surawicz, CM; Washington, P; Weinberg, CR, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
prostanoidThe family of natural prostaglandins and prostaglandin-like compounds including prostacyclins and thromboxanes.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (76)

TimeframeStudies, This Drug (%)All Drugs %
pre-199065 (85.53)18.7374
1990's11 (14.47)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.24 (24.57)
Research Supply Index4.63 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials22 (27.50%)5.53%
Reviews1 (1.25%)6.00%
Case Studies2 (2.50%)4.05%
Observational0 (0.00%)0.25%
Other55 (68.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]